Skip to content
DataLookout
Menu

hiPSSSNCT07650565

Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 7 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Primary endpoints: details revised at 4 of 4 entries
    • Primary and study completion dates: Mar 2028 to Apr 2028
    • Start date changed from estimate of Sep 2026 to Oct 27, 2026
    • Secondary endpoints: details revised at 9 of 9 entries
    • Study description shortened, about 197 words
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Rate of successful iPSC line generation from PBMCs in diffuse/severe systemic sclerosis patients
Timeframe: At inclusion (Day 0 blood draw; iPSC generation assessed within approximately 3 months post-collection)
Rate of successful differentiation of iPSCs into at least one target functional cell type in localized/non-complicated systemic sclerosis patients
Timeframe: At inclusion (assessed within approximately 6 months post-collection)
Rate of successful iPSC line generation from PBMCs in localized/non-complicated systemic sclerosis patients
Timeframe: At inclusion (Day 0 blood draw; iPSC generation assessed within approximately 3 months post-collection)
Rate of successful differentiation of iPSCs into at least one target functional cell type in diffuse/severe systemic sclerosis patients
Timeframe: At inclusion (assessed within approximately 6 months post-collection)

Secondary (9)

Change in cardiomyocyte differentiation efficiency following autologous autoantibody exposure
Change in macrophage differentiation and inflammatory cytokine secretion following autologous autoantibody exposure
Functional characterization of iPSC-derived cardiomyocytes - spontaneous beating activity
Molecular characterization of iPSC-derived cardiomyocytes - cardiac marker expression
Phenotypic characterization of iPSC-derived macrophages - pan-macrophage surface marker expression
Show 4 moreShow less
Transcriptomic characterization of iPSC-derived macrophages - inflammatory gene regulation
Characterization of iPSC-derived immune cells - antigen-presenting cell differentiation efficiency
Characterization of iPSC-derived bronchial epithelial cells - stepwise differentiation efficiency
Functional characterization of iPSC-derived bronchial air-liquid interface epithelium (iALI) - barrier integrity and mucociliary function

Arms and interventions

Participants with Systemic Sclerosis and Healthy ControlsExperimental

Participants undergo blood sample collection for generation of induced pluripotent stem cells (iPSCs) and in vitro cellular and tissue modeling.

Procedures: Blood Sample Collection

Sites

1 site in 1 country

  • University hospital MontpellierMontpellier, France